Please login to the form below

Not currently logged in
Email:
Password:

Sanofi pasteur launches new €100m vaccine plant

Sanofi Pasteur has opened a new €100m vaccination production plant in France capable of rapid turned around to make immunisation drugs in the event of an influenza pandemic
Sanofi Pasteur has opened a new €100m vaccination production plant in France capable of rapid turned around to make immunisation drugs in the event of an influenza pandemic.

The company, which is a division of sanofi-aventis, says its inaugural production site in Val de Reuil is equipped with state-of-the-art automated technology and is designed to cope with the rising demand for vaccination medicines. Should the World Health Organisation (WHO) identify a pandemic of influenza, Sanofi Pasteur claims that the facility can be turned around to produce enough vaccines to meet the requirements of such an occurrence.

Wayne Pisano, president and CEO of Sanofi Pasteur, who opened the French production plant, said that the demand for vaccines will double by the year 2016.

"Sanofi Pasteur's commitment to global health is exemplified by significant investments in vaccine production infrastructures," he said.

"The new facility will provide a high-end production work environment for dedicated people who produce vaccines for the world."

Funding for this new site is set to boost the level of production to 200 million syringes filled and shipped ever year, a significant increase from the current level of two million vaccines per annum.

A further €100m is being spent on constructing a building in Val de Reuil for the formulation of vaccines. This forms part of a larger €600m investment programme initiated by the company in 2005. Pisano is confident that the new facilities will help the firm provide the global healthcare community with high quality vaccinations.

26th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics